The "Summary Page" provides a listing of drug names and safety labeling sections revised.
The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and/or WARNINGS sections:
Avodart (dutasteride)
Bepreve (bepotastine besilate) 1.5% ophthalmic
CellCept (mycophenolate mofetil)
CellCept (mycophenolate mofetil hydrochloride)
Estraderm (estradiol) transdermal
Helidac Therapy (bismuth subsalicylate, metronidazole and tetracycline hydrochloride)
Incivek (telaprevir)
Jalyn (dutasteride and tamsulosin HCL)
Methergine (methylergonovine maleate)
Myfortic (mycophenolic acid)
Noxafil (posaconazole)
Prezista (darunavir)
Prinivil (lisinopril) tablets and
Prinzide(lisinopril/hydrochlorothiazide)
Privigen Immune Globulin Intravenous (Human) 10%
Stelara (ustekinumab)
Strattera (atomoxetine hydrochloride)
Sustiva (efavirenz)
Vesicare (solifenacin succinate)
Zithromax (azithromycin)
Companies in this press-release
